Mira Pharmaceuticals Inc. has reported continued progress toward IND-enabling studies of its two lead preclinical programs, MIRA-55, an investigational oral nonopioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.